{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:54:05Z","timestamp":1770234845886,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":219,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>PD-1 blockade has been approved for head and neck squamous cell carcinoma (HNSCC) patients. However, many HNSCC patients do not respond to this treatment, and other tumor microenvironmental factors may promote resistance to PD-1 blockade. We previously identified increased expression of the inhibitory receptor NKG2A on CD8+ T cells in HNSCC tumors compared with T cells in matching PBMC samples. Mechanisms that promote NKG2A expression and the role of NKG2A on human T cells in the tumor microenvironment, however, are uncertain. In this study, we show that tumor-conditioned media (TCM) of HNSCC cancer cell lines or ascites fluid from colorectal carcinoma patients is sufficient to induce the expression of NKG2A and other inhibitory receptors on activated CD8+ T cells isolated from PBMCs of healthy donors. Boiling or small molecular mass cutoff filtering did not eliminate the effect of TCM, suggesting that a small molecule promotes NKG2A. T cell activation in TCM decreased the basal and maximal mitochondrial respiration to metabolically restrain CD8+ T cells. Functionally, T cell activation in TCM reduced CD8+ T cell cytotoxicity as shown by lower production of cytokines, granzyme B, and perforin. Furthermore, TCM prevented CD8+ T cells from killing cancer cells in response to an anti-CD19\/anti-CD3 bispecific T cell engager. Thus, a small secreted molecule from HNSCC cells can induce NKG2A expression and promote T cell dysfunction. Our findings may lead to targets for novel cancer therapies or biomarkers for NKG2A blockade response and provide a model to study T cell dysfunction and impaired metabolism.<\/jats:p>","DOI":"10.4049\/immunohorizons.2400046","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T13:23:34Z","timestamp":1719408214000},"page":"464-477","source":"Crossref","is-referenced-by-count":2,"title":["Cancer Cell Small Molecule Secretome Induces the Immune Checkpoint NKG2A and Dysfunction of Human CD8+ T Cells"],"prefix":"10.1093","volume":"8","author":[{"given":"Gabriel J","family":"Rodriguez-Garcia","sequence":"first","affiliation":[{"name":"Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8195-9613","authenticated-orcid":false,"given":"Diana K","family":"Graves","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, TN"},{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad B","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Surgery, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-4461","authenticated-orcid":false,"given":"Kamran","family":"Idrees","sequence":"additional","affiliation":[{"name":"Department of Surgery, Vanderbilt University Medical Center , Nashville, TN"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8434-4561","authenticated-orcid":false,"given":"Young J","family":"Kim","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN"},{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Vanderbilt University Medical Center , Nashville, TN"},{"name":"Regeneron Pharmaceutical , Tarrytown, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Korrer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4106-3396","authenticated-orcid":false,"given":"Jeffrey C","family":"Rathmell","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, TN"},{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN"},{"name":"Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center , Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"2025010608554764700_r1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4065\/82.7.878","article-title":"Oral cancer","volume":"82","author":"Kademani","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"2025010608554764700_r2","doi-asserted-by":"crossref","first-page":"24194","DOI":"10.18632\/oncotarget.8254","article-title":"Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis","volume":"7","author":"Vermeer","year":"2016","journal-title":"Oncotarget"},{"key":"2025010608554764700_r3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2025010608554764700_r4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"2025010608554764700_r5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","article-title":"FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy","volume":"22","author":"Larkins","year":"2017","journal-title":"Oncologist"},{"key":"2025010608554764700_r6","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1158\/1078-0432.CCR-18-3944","article-title":"Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use","volume":"25","author":"Ferris","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2025010608554764700_r7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1078-0432.CCR-19-2209","article-title":"Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen-specific T cells","volume":"26","author":"Friedman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2025010608554764700_r8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","article-title":"Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma","volume":"12","author":"Mei","year":"2020","journal-title":"Int. J. Oral Sci."},{"key":"2025010608554764700_r9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/eji.1830270230","article-title":"The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules","volume":"27","author":"Carretero","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"2025010608554764700_r10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J. Clin. Invest."},{"key":"2025010608554764700_r11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1073\/pnas.95.3.1172","article-title":"HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94\/NKG2A in superantigen- or alloantigen-activated CD8+ T cells","volume":"95","author":"Mingari","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025010608554764700_r12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0923-2494(97)84216-2","article-title":"HLA class-I-specific inhibitory receptor in human T lymphocytes: interference with T-cell functions","volume":"148","author":"Mingari","year":"1997","journal-title":"Res. Immunol."},{"key":"2025010608554764700_r13","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.156.12.4531","article-title":"Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases","volume":"156","author":"Olcese","year":"1996","journal-title":"J. Immunol."},{"key":"2025010608554764700_r14","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"2025010608554764700_r15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41379-019-0322-9","article-title":"The inhibitory receptor CD94\/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE\/\u03b22m overexpression","volume":"33","author":"Eug\u00e8ne","year":"2020","journal-title":"Mod. Pathol."},{"key":"2025010608554764700_r16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jnen\/64.6.523","article-title":"HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo","volume":"64","author":"Wischhusen","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2025010608554764700_r17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02114975","article-title":"Polymorphism in the human class I MHC locus HLA-E in Japanese","volume":"32","author":"Ohya","year":"1990","journal-title":"Immunogenetics"},{"key":"2025010608554764700_r18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/eji.1830270517","article-title":"The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9","volume":"27","author":"Braud","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"2025010608554764700_r19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.20072525","article-title":"CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence","volume":"205","author":"Petrie","year":"2008","journal-title":"J. Exp. Med."},{"key":"2025010608554764700_r20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41571-019-0182-8","article-title":"The NKG2A immune checkpoint\u2014a new direction in cancer immunotherapy","volume":"16","author":"Creelan","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2025010608554764700_r21","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"key":"2025010608554764700_r22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/ijc.26453","article-title":"HLA-E\/\u03b22 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression","volume":"131","author":"Bossard","year":"2012","journal-title":"Int. J. Cancer"},{"key":"2025010608554764700_r23","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.18632\/oncotarget.6506","article-title":"The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma","volume":"7","author":"Talebian Yazdi","year":"2016","journal-title":"Oncotarget"},{"key":"2025010608554764700_r24","doi-asserted-by":"crossref","first-page":"e1052213","DOI":"10.1080\/2162402X.2015.1052213","article-title":"Non-classical HLA-class I expression in serous ovarian carcinoma: correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis","volume":"5","author":"Andersson","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025010608554764700_r25","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.1073\/pnas.1100354108","article-title":"HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes","volume":"108","author":"Gooden","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025010608554764700_r26","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"25","author":"Vermorken","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2025010608554764700_r27","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"2025010608554764700_r28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood-2010-11-317396","article-title":"Calcineurin-dependent negative regulation of CD94\/NKG2A expression on naive CD8+ T cells","volume":"118","author":"Cho","year":"2011","journal-title":"Blood"},{"key":"2025010608554764700_r29","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ijc.33859","article-title":"NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division","volume":"150","author":"Borst","year":"2022","journal-title":"Int. J. Cancer"},{"key":"2025010608554764700_r30","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-04-2108","article-title":"Up-regulation of inhibitory natural killer receptors CD94\/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma","volume":"65","author":"Sheu","year":"2005","journal-title":"Cancer Res."},{"key":"2025010608554764700_r31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y","article-title":"Transforming growth factor-beta-induced expression of CD94\/NKG2A inhibitory receptors in human T lymphocytes","volume":"29","author":"Bertone","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"2025010608554764700_r32","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.4049\/jimmunol.168.10.4864","article-title":"Expression of CD94\/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy","volume":"168","author":"Derre","year":"2002","journal-title":"J. Immunol."},{"key":"2025010608554764700_r33","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.3389\/fimmu.2019.03002","article-title":"CD8+ T cells form the predominant subset of NKG2A+ cells in human lung cancer","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"2025010608554764700_r34","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/eji.1830201008","article-title":"A new surface antigen on intraepithelial lymphocytes in the intestine","volume":"20","author":"Kilshaw","year":"1990","journal-title":"Eur. J. Immunol."},{"key":"2025010608554764700_r35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.immuni.2016.08.009","article-title":"The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"2025010608554764700_r36","doi-asserted-by":"crossref","first-page":"e93411","DOI":"10.1172\/jci.insight.93411","article-title":"Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma","volume":"2","author":"Siska","year":"2017","journal-title":"JCI Insight"},{"key":"2025010608554764700_r37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat. Med."},{"key":"2025010608554764700_r38","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat. Commun."},{"key":"2025010608554764700_r39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"2025010608554764700_r40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1158\/2326-6066.CIR-18-0885","article-title":"Enriched HLA-E and CD94\/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses","volume":"7","author":"Abd Hamid","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"2025010608554764700_r41","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","article-title":"Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer","volume":"28","author":"Obradovic","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"2025010608554764700_r42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-021-03862-z","article-title":"Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer","volume":"597","author":"Eberhardt","year":"2021","journal-title":"Nature"},{"key":"2025010608554764700_r43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/8\/6\/464\/60189042\/ih2400046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/8\/6\/464\/60189042\/ih2400046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:57:17Z","timestamp":1736153837000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/8\/6\/464\/7817056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.4049\/immunohorizons.2400046","relation":{},"ISSN":["2573-7732"],"issn-type":[{"value":"2573-7732","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6,1]]}}}